Business · 07/04/2015Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product
Summary
The FDA has issued a priority review voucher to United Therapeutics Corporation for its rare pediatric disease product application, UNITUXIN, which is manufactured by the company and meets the criteria set by the FD&C Act and FDASIA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →